Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical and rare disease company with approved and investigational therapies targeting rare liver and neurodevelopmental conditions. The Mirum news feed on Stock Titan aggregates company announcements, press releases and corporate disclosures so readers can follow how its commercial portfolio and pipeline evolve over time.
Investors and followers of MIRM can review news about LIVMARLI (maralixibat), CHOLBAM (cholic acid) and CTEXLI (chenodiol), including regulatory updates, commercial milestones and clinical study developments. Coverage also includes updates on clinical-stage programs such as volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis delta virus (HDV) in connection with the proposed Bluejay Therapeutics acquisition, and MRM-3379 for Fragile X syndrome (FXS).
News items commonly highlight Mirum’s participation in healthcare and investor conferences, private placement financings, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and material events reported via Form 8-K filings. Company press releases also discuss regulatory designations, study initiations, enrollment updates and planned timelines for key clinical readouts, as described in Mirum’s own communications.
This page offers a centralized view of Mirum-related headlines, allowing readers to track commercial performance commentary, pipeline progress and transaction announcements in one place. For users researching MIRM stock or the company’s rare disease programs, the news feed provides direct access to the narrative Mirum shares with the market.
Mirum Pharmaceuticals (NASDAQ:MIRM) has scheduled its second quarter 2025 financial results announcement and conference call for August 6, 2025 at 4:30 p.m. ET. The company will discuss Q2 2025 financial performance and provide updates on recent corporate developments.
Investors can join via phone using U.S. toll-free number +1 833 470 1428 or international number +1 404 975 4839 with access code 448461. A webcast option is available through Mirum's website Events & Presentations section, with replay access for 30 days following the call.
Mirum Pharmaceuticals (NASDAQ:MIRM) announced inducement grants to two new employees under its 2020 Inducement Plan. The compensation package includes 14,460 non-qualified stock options at an exercise price of $53.01 per share and 7,220 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually, subject to continued employment.
Mirum Pharmaceuticals (Nasdaq: MIRM), a biopharmaceutical company specializing in rare and orphan diseases, has announced its participation in two upcoming investor conferences in May 2025. The company will attend the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20th and deliver a company presentation at the RBC Capital Markets Global Healthcare Conference on May 21st at 9:00 AM ET. Interested parties can access webcast links and additional information through the Investors and Media section of Mirum's corporate website.
Mirum Pharmaceuticals (NASDAQ: MIRM) announced inducement awards granted to eight new employees on May 9, 2025. The awards, approved by the Compensation Committee, include:
- Stock options to purchase 53,230 shares at $44.27 per share (closing price on May 9), vesting over 4 years with 25% vesting after one year and remaining monthly over 36 months
- 26,585 restricted stock units (RSUs) vesting over 3 years with 33% vesting annually
The grants were made under Mirum's 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), subject to continued employment.
Mirum Pharmaceuticals presented promising 28-week data from its Phase 2b VANTAGE study evaluating volixibat for cholestatic pruritus in primary biliary cholangitis (PBC) patients at EASL. The study showed statistically significant improvements in pruritus (itching) and numeric improvements in fatigue, the two most burdensome PBC symptoms.
Key findings include:
- 70% of volixibat-treated patients achieved ≥50% reduction in serum bile acids
- Statistically significant 3.78-point reduction in ItchRO from baseline in the combined dose group
- Both 20mg and 80mg BID doses showed similar efficacy
- Improvements in quality of life measures and reductions in IL-31 inflammatory biomarker
The most common adverse event was mild to moderate diarrhea (77%). Based on similar efficacy and safety results, the 20mg BID dose was selected for the confirmatory portion of the VANTAGE study.
Mirum Pharmaceuticals (NASDAQ: MIRM) has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss both the financial performance and recent corporate developments.
Investors and interested parties can access the call through multiple channels:
- U.S./Toll-Free: +1 833 470 1428
- International: +1 404 975 4839
- Passcode: 549600
Additionally, a webcast will be available through the Events & Presentations section on Mirum's website. For those unable to attend live, a replay of the webcast will remain accessible for 30 days following the call.
Mirum Pharmaceuticals (NASDAQ: MIRM) has announced upcoming data presentations at three major medical congresses in May 2025: Digestive Disease Week (DDW) in San Diego, European Association for the Study of the Liver (EASL) in Amsterdam, and ESPGHAN in Helsinki.
A key highlight includes new 28-week data from the Phase 2b VANTAGE study of volixibat in PBC patients, showing significant improvements in cholestatic pruritus. The study demonstrated that 70% of volixibat-treated patients achieved ≥50% reduction in serum bile acid levels, with improvements in fatigue and sleep. The most common side effect was mild to moderate diarrhea.
The presentations will feature data from LIVMARLI and volixibat studies across multiple sessions, including oral presentations, posters, and symposiums focusing on cholestatic liver diseases, PFIC, and Alagille syndrome treatment outcomes.